{
  "created_at": "Mon Aug 08 12:4:25 +0000 2022",
  "id_str": "1556589619663233024",
  "full_text": "Pfizer will buy Global Blood Therapeutics for $5.4 billion, people familiar with the matter say, giving it a foothold in the treatment of sickle-cell disease",
  "display_text_range": [
    0,
    157
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": []
  },
  "user": {
    "name": "The Wall Street Journal",
    "screen_name": "WSJ",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/971415515754266624/zCX0q9d5_normal.jpg"
  },
  "retweet_count": 32,
  "favorite_count": 104,
  "original_created_at": "Mon Aug 08 10:34:20 +0000 2022",
  "localize": [
    {
      "locale": "ja",
      "full_text": "ファイザーがグローバル・ブラッド・セラピューティクスを54億ドルで買収し、鎌状赤血球症の治療で足がかりを得ると、関係者が述べている。"
    },
    {
      "locale": "zh",
      "full_text": "熟悉此事的人士说，辉瑞公司将以54亿美元的价格收购全球血液治疗公司，使其在治疗镰状细胞疾病方面拥有立足之地。"
    },
    {
      "locale": "zh-Hant",
      "full_text": "熟悉此事的人士說，輝瑞公司將以54億美元的價格收購全球血液治療公司，使其在治療鐮狀細胞疾病方面擁有立足之地。"
    }
  ]
}